Silmara Navarro Pennini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Silmara Navarro Pennini has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Paula Frassinetti Bessa Rebello
Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta, Manaus, AM, Brazil
10 shared publications - Sinésio Talhari
Programa de Pós‐Graduação em Ciências Aplicadas à Dermatologia Universidade do Estado do Amazonas Manaus AM Brazil
7 shared publications - Maria das Graças Vale Barbosa Guerra
Affiliations Universidade do Estado do Amazonas, Manaus, Amazonas, Brasil, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brasil, Fundação Hospitalar Alfredo da Matta, Manaus, Amazonas, Brasil
5 shared publications - Jorge Augusto de Oliveira Guerra
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Brasil; Universidade do Estado do Amazonas, Brasil; Universidade do Estado do Amazonas, Brasil; Universidade do Estado do Amazonas, Brasil; Centro Universitário CEUNI-FAMETRO, Brasil
3 shared publications - André Luiz Leturiondo
Programa de Pós‐Graduação em Ciências Aplicadas à Dermatologia Universidade do Estado do Amazonas Manaus Amazonas Brazil
2 shared publications - Camila Gurgel dos Santos da Silva
Fundação Hospitalar Alfredo da Matta de Dermatologia Manaus Amazonas Brazil
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1)
Advances and Challenges Regarding American Tegumentary Leishmaniasis in the Amazon: Scientific, Epidemiological and Public Health Perspectives
American tegumentary leishmaniasis (ATL) remains a significant public health problem in the Americas, with the Amazon region standing out in Brazil for its high number of cases. This article aimed to present advances in the understanding of epidemiology, diagnosis, treatment and control of ATL in the state of Amazonas over the past decades. This study is a narrative review of scientific studies published in the literature between 2011 and 2025, retrieved from databases such as PubMed and SciELO, as well as public data from the Notifiable Diseases Information System (SINAN), official reports from the Ministry of Health and technical notes from the Amazonas Health Surveillance Foundation. The evolution of disease incidence is reported, highlighting the predominance of Leishmania (Viannia) guyanensis and the environmental factors associated with the increase in cases, such as deforestation and unplanned urbanization. Advances in diagnostic strategies include the expanded use of molecular techniques and the strengthening of the primary healthcare network. Regarding therapy, clinical trials with drugs such as pentamidine, miltefosine, tamoxifen and itraconazole have demonstrated their efficacy in treatment. The review also includes socio-environmental, genetic and experimental studies that have contributed to a better understanding of the disease. It emphasizes the need to establish a priority agenda that includes the use of telemedicine and the institutionalization of collaborative research for therapeutic innovation, integration between research and healthcare services and strategies adapted to the Amazonian context. Regional scientific advances can support more effective control policies and reduce the burden of ATL in this highly endemic setting.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1)
Open AccessAdvances and Challenges Regarding American Tegumentary Leishmaniasis in the Amazon: Scientific, Epidemiological and Public Health Perspectives
American tegumentary leishmaniasis (ATL) remains a significant public health problem in the Americas, with the Amazon region standing out in Brazil for its high number of cases. This article aimed to present advances in the understanding of epidemiology, diagnosis, treatment and control of ATL in the state of Amazonas over the past decades. This study is a narrative review of scientific studies published in the literature between 2011 and 2025, retrieved from databases such as PubMed and SciELO, as well as public data from the Notifiable Diseases Information System (SINAN), official reports from the Ministry of Health and technical notes from the Amazonas Health Surveillance Foundation. The evolution of disease incidence is reported, highlighting the predominance of Leishmania (Viannia) guyanensis and the environmental factors associated with the increase in cases, such as deforestation and unplanned urbanization. Advances in diagnostic strategies include the expanded use of molecular techniques and the strengthening of the primary healthcare network. Regarding therapy, clinical trials with drugs such as pentamidine, miltefosine, tamoxifen and itraconazole have demonstrated their efficacy in treatment. The review also includes socio-environmental, genetic and experimental studies that have contributed to a better understanding of the disease. It emphasizes the need to establish a priority agenda that includes the use of telemedicine and the institutionalization of collaborative research for therapeutic innovation, integration between research and healthcare services and strategies adapted to the Amazonian context. Regional scientific advances can support more effective control policies and reduce the burden of ATL in this highly endemic setting.
- Open Access
- 9 January 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (2) , 355-357
Telemedicine (mobile-Health) as an alternative in the follow-up of patients in a randomized clinical trial for the treatment of cutaneous leishmaniasis in the state of Amazonas, Brazil
- 9 January 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (2) , 355-357
Open AccessTelemedicine (mobile-Health) as an alternative in the follow-up of patients in a randomized clinical trial for the treatment of cutaneous leishmaniasis in the state of Amazonas, Brazil
- 3 December 2024
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (1) , 65-69
Sporothrix brasiliensis as the major causative species of the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon
Background: Sporotrichosis is a neglected tropical disease and the most common subcutaneous mycosis, mainly caused by Sporothrix species, particularly S. brasiliensis, S. schenckii and S. globosa, which exhibit varying biological behaviours and virulence. The epidemic of sporotrichosis in Brazil, initiated in Rio de Janeiro in the late 1990s, rapidly spread to other states, including Amazonas in 2021. This study aimed to identify the specific Sporothrix species responsible for the human sporotrichosis outbreak in the Brazilian Amazon.Methods: A cross‐sectional study was conducted by enrolling clinically suspected cases of sporotrichosis attended at a reference dermatologic centre, in Manaus (Brazil). Biological material was collected from their skin lesions for culture (Mycosel) and for species identification (qPCR).Results: Sporothrix cultures were obtained from 150 cases. Sporotrichosis predominantly affected females (67.3%), aged 44.5 years on average, with lymphocutaneous lesions (72.7%). Sporothrix brasiliensis was identified in 89.3% of patients. Up to 83.3% of these patients reported contact with cats previously to the skin lesion, and the time‐spatial progression of the human cases followed the notification of cases in cats, in the metropolitan region of Manaus.Conclusion: Sporothrix brasiliensis is the dominant species in the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon, with cats identified as the primary vectors. Effective sanitary control measures, education and responsible pet ownership are crucial to mitigating zoonotic sporotrichosis' impact in Brazil and preventing its spread to neighbouring Latin American cities.
- 3 December 2024
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (1) , 65-69
Sporothrix brasiliensis as the major causative species of the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon
Background: Sporotrichosis is a neglected tropical disease and the most common subcutaneous mycosis, mainly caused by Sporothrix species, particularly S. brasiliensis, S. schenckii and S. globosa, which exhibit varying biological behaviours and virulence. The epidemic of sporotrichosis in Brazil, initiated in Rio de Janeiro in the late 1990s, rapidly spread to other states, including Amazonas in 2021. This study aimed to identify the specific Sporothrix species responsible for the human sporotrichosis outbreak in the Brazilian Amazon.Methods: A cross‐sectional study was conducted by enrolling clinically suspected cases of sporotrichosis attended at a reference dermatologic centre, in Manaus (Brazil). Biological material was collected from their skin lesions for culture (Mycosel) and for species identification (qPCR).Results: Sporothrix cultures were obtained from 150 cases. Sporotrichosis predominantly affected females (67.3%), aged 44.5 years on average, with lymphocutaneous lesions (72.7%). Sporothrix brasiliensis was identified in 89.3% of patients. Up to 83.3% of these patients reported contact with cats previously to the skin lesion, and the time‐spatial progression of the human cases followed the notification of cases in cats, in the metropolitan region of Manaus.Conclusion: Sporothrix brasiliensis is the dominant species in the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon, with cats identified as the primary vectors. Effective sanitary control measures, education and responsible pet ownership are crucial to mitigating zoonotic sporotrichosis' impact in Brazil and preventing its spread to neighbouring Latin American cities.
- 8 November 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (12) , 871-880
Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non‐inferiority clinical trial
Objective: To determine whether a combination of a single intramuscular (IM) dose of pentamidine (7 mg/kg) followed by oral tamoxifen 40 mg/day for 20 days is non‐inferior to three IM doses of pentamidine 7 mg/kg in the treatment of cutaneous leishmaniasis with a margin of 15%.Methods: Phase II, randomised, controlled, open‐label, non‐inferiority clinical trial. Primary outcome was the complete healing of the lesions 6 months after starting treatment. Secondary outcomes were healing 3 months after starting treatment and determining the presence and severity of adverse effects (AE).Results: The research was concluded with 49 patients; Leishmania (Viannia) guyanensis was the most frequent species isolated. In the primary outcome, 18 (72%) (95% CI: 52.4%–85.7%) of the 25 patients allocated to the intervention group and 24 (100%) (95% CI: 86.2%–100%) of the control group (p = 0.015) met the established criteria of cure. There was no AE with tamoxifen.Conclusion: Although a 72% cure rate presented by the combination of tamoxifen and pentamidine was lower than in the control group that achieved a 100% cure, it is still a safe and is a clinically relevant result. It indicates that the therapeutic scheme evaluated may be a promising option for populations in remote areas, however it should be further studied, in order to include a larger number of patients.
- 8 November 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (12) , 871-880
Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non‐inferiority clinical trial
Objective: To determine whether a combination of a single intramuscular (IM) dose of pentamidine (7 mg/kg) followed by oral tamoxifen 40 mg/day for 20 days is non‐inferior to three IM doses of pentamidine 7 mg/kg in the treatment of cutaneous leishmaniasis with a margin of 15%.Methods: Phase II, randomised, controlled, open‐label, non‐inferiority clinical trial. Primary outcome was the complete healing of the lesions 6 months after starting treatment. Secondary outcomes were healing 3 months after starting treatment and determining the presence and severity of adverse effects (AE).Results: The research was concluded with 49 patients; Leishmania (Viannia) guyanensis was the most frequent species isolated. In the primary outcome, 18 (72%) (95% CI: 52.4%–85.7%) of the 25 patients allocated to the intervention group and 24 (100%) (95% CI: 86.2%–100%) of the control group (p = 0.015) met the established criteria of cure. There was no AE with tamoxifen.Conclusion: Although a 72% cure rate presented by the combination of tamoxifen and pentamidine was lower than in the control group that achieved a 100% cure, it is still a safe and is a clinically relevant result. It indicates that the therapeutic scheme evaluated may be a promising option for populations in remote areas, however it should be further studied, in order to include a larger number of patients.
- Open Access
- 1 March 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (2) , 258-259
Hanseníase paucibacilar com lesão única: estudo retrospectivo de 75 casos tratados com o esquema ROM
- 1 March 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (2) , 258-259
Open AccessHanseníase paucibacilar com lesão única: estudo retrospectivo de 75 casos tratados com o esquema ROM
- Open Access
- 15 January 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (2) , 258-259
Single-lesion paucibacillary leprosy: a retrospective study of 75 cases treated with the ROM scheme
- 15 January 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (2) , 258-259
Open AccessSingle-lesion paucibacillary leprosy: a retrospective study of 75 cases treated with the ROM scheme
- Open Access
- 1 December 2021
- Published by Lepra in Leprosy Review
- Vol. 92 (4) , 421-426
Erythema nodosum leprosum and active leprosy after ChAdOx1-S/nCoV-19 recombinant vaccine. A report of two cases
Leprosy reactions are acute inflammatory processes, immunologically mediated that may be precipitated by many factors, including infections and vaccines. They are classified in Type 1 Reaction or Reversal Reaction, and Type 2 Reaction (T2LR). The most common clinical manifestation of T2LR is the erythema nodosum (EN), and, because of this, it is also called Erythema Nodosum Leprosum (ENL). Reactions can occur before, during or after the diagnosis and treatment of leprosy. We present two cases of ENL in patients who were released from treatment, and had received the first dose of ChAdOx1-S/nCoV-19 vaccine just a few days before the appearance of the skin lesions. One of them also had signs of active multibacillary leprosy. Reports of erythema nodosum related to COVID-19 disease have been published, but to our knowledge, this report is the first to describe cases of ENL related to SARS-CoV-2 vaccines.
- 1 December 2021
- Published by Lepra in Leprosy Review
- Vol. 92 (4) , 421-426
Open AccessErythema nodosum leprosum and active leprosy after ChAdOx1-S/nCoV-19 recombinant vaccine. A report of two cases
Leprosy reactions are acute inflammatory processes, immunologically mediated that may be precipitated by many factors, including infections and vaccines. They are classified in Type 1 Reaction or Reversal Reaction, and Type 2 Reaction (T2LR). The most common clinical manifestation of T2LR is the erythema nodosum (EN), and, because of this, it is also called Erythema Nodosum Leprosum (ENL). Reactions can occur before, during or after the diagnosis and treatment of leprosy. We present two cases of ENL in patients who were released from treatment, and had received the first dose of ChAdOx1-S/nCoV-19 vaccine just a few days before the appearance of the skin lesions. One of them also had signs of active multibacillary leprosy. Reports of erythema nodosum related to COVID-19 disease have been published, but to our knowledge, this report is the first to describe cases of ENL related to SARS-CoV-2 vaccines.
- Open Access
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (4) , 500-502
Evolução clínica da função neural em série de casos de neuropatia hansênica após neurólise ulnar
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (4) , 500-502
Open AccessEvolução clínica da função neural em série de casos de neuropatia hansênica após neurólise ulnar
- Open Access
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (4) , 500-502
Clinical evolution of neural function in a series of leprosy neuropathy cases after ulnar neurolysis
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (4) , 500-502
Open AccessClinical evolution of neural function in a series of leprosy neuropathy cases after ulnar neurolysis
- Open Access
- 1 November 2019
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 94 (6) , 765-767
Acidente por milípede com lesão dermatológica inusitada
- 1 November 2019
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 94 (6) , 765-767
Open AccessAcidente por milípede com lesão dermatológica inusitada